Reeling From Lehman Bros-linked Loss, China’s 3SBio Aims To Bioengineer Its Own Recovery
This article was originally published in PharmAsia News
Executive Summary
BEIJING - Stung by a loss of nearly $3 million in late 2008 tied to the U.S. financial meltdown, leading Chinese biopharmaceutical outfit 3SBio is laying the drug development groundwork for a profit rebound this year and next
You may also be interested in...
3SBio Sees Strong Growth In Q1 Driven By Oncology Product EPIAO
SHANGHAI - Biotech company 3SBio saw revenues increase 23.7 percent in the first quarter of 2009, driven by the company's leading recombinant human erythropoietin injection EPIAO, the only approved EPO drug in China
3SBio Sees Strong Growth In Q1 Driven By Oncology Product EPIAO
SHANGHAI - Biotech company 3SBio saw revenues increase 23.7 percent in the first quarter of 2009, driven by the company's leading recombinant human erythropoietin injection EPIAO, the only approved EPO drug in China
3SBio Files For Approval For Interleukin-2 NuLeusin
SHANGHAI - 3SBio filed an application for the approval of NuLeusin with China's State FDA Nov. 10, hoping to make it the first product of its kind on the Chinese market, the Shenyang-based company announced